

Monoclonal Antibody to Rituximab - FITC

Alternate names:	MabThera, Rituxan
Catalog No.:	AM05879FC-N
Quantity:	0.1 mg
Concentration:	0.1 mg/ml
Background:	Rituximab is a therapeutic reagent directed against the human CD20 cell surface antigen.
Host / Isotype:	Rat / IgG2a
Clone:	MB2 A4
Immunogen:	F(ab)2 fragment of Rituximab
Format:	State: Liquid purified Ig fraction. Purification: Affinity Chromatography on Protein G. Buffer System: PBS, pH 7.4 with 0.09% Sodium Azide as preservative and 1% BSA as stabilizer. Label: FITC
Applications:	Flow Cytometry: Use 10 µl of neat antibody to label 10 ⁶ cells in 100 µl. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Specificity:	This antibody specifically recognises the idiotypic determinants expressed by the Rituximab humanised monoclonal antibody. This antibody does not recognise other CD20 antibodies. It has been used to detect Rituximab bound to the surface of the Raji B cell line, however detection of Rituximab bound <i>'in vivo'</i> to B-CLL cells has not been demonstrated. It is possible that complement deposition on Rituximab opsonised cells inhibits binding of the anti-Rituximab antibody to cell bound Rituximab (3).
Storage:	Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Shelf life: One year from despatch.
General Readings:	1. Bayne, M. et al. (2003) Phase I/II study of fractionated radioimmunotherapy in relapsed low grade non Hodgkin lymphoma. Br. J. Cancer. 88 : S38. 2. Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PW, Glennie MJ. Apparent modulation of CD20 by rituximab: an alternative explanation. Blood. 2004 May 15;103(10):3989-90; author reply 3990-1. PubMed PMID: 15121717. 3. 4. Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PW, Glennie MJ. Apparent modulation of CD20 by rituximab: an alternative explanation. Blood. 2004 May 15;103(10):3989-90; author reply 3990-1. PubMed PMID: 15121717. 5. Beum PV, Kennedy AD, Li Y, Pawluczkojczyk AW, Williams ME, Taylor RP. Complement

For research and in vitro use only. Not for diagnostic or therapeutic work.

Material Safety Datasheets are available at www.acris-antibodies.com or on request.

Antibody Hotline - Technical Questions - Antibody Location Service
Free Call: 0800-2274746 (Germany only) - www.acris-antibodies.com



activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab. J Immunol Methods. 2004 Nov;294(1-2):37-42. PubMed PMID: 15604014.

For research and in vitro use only. Not for diagnostic or therapeutic work.

Material Safety Datasheets are available at www.acris-antibodies.com or on request.

Antibody Hotline - Technical Questions - Antibody Location Service
Free Call: 0800-2274746 (Germany only) - www.acris-antibodies.com